SOFOKAST PLUS TABLETS –
Sofokast plus tablets, which contain 400 mg Sofosbuvir is a nucleotide polymerase inhibitor, and includes antiviral drugs direct action. sofosbuvir is exposed to have a high barrier to growth resistance and inhibits the Cb NS5B Hep protein. Thus, Sofosbuvir interferes with the enzyme RNA polymerase by a cell worker who can perform the reproduction process. Consequently, Sofosbuvir stops hepatitis C virus replication and reduces the amount of Hep C virus in the liver. Sofosbuvir also acts to reduce liver damage and improve liver function.
Sofokast plus tablets also contains daclatasvir, a direct-acting antiviral drug that is indicated for a patient affected by hepatitis C virus infection. It will target the Hep C virus and stops numerous steps in the HCV reproduction process by preventing viral particles from making copies themselves, and helps the body remove the virus from the blood.
Peak plasma concentration is 0. 5-2 h after dose for 40% Sofosbuvir and in metabolite GS-331007 peak plasma concentration obtained 2-4 hours after administration where, as in Daclatasvir, peak plasma plasma concentration is within 2 hours after dose administration and bioavailability is 67%
Sofosbuvir 400 mg and metabolite do not affect fatty flour. Hence, Sofosbuvir is managed without food. In Daclatasvir, 60 mg of the drug was not taken with or without food.
Sofosbuvir 400 mg is about 51-65% bound to human plasma proteins, and the metabolite GS-331007 has minimal binding to human plasma proteins. And in Daclatasvir 60 mg protein binding protein is 99%
In the liver, Sofosbuvir 400 mg is extensively metabolized (4% and> 90%) to be converted into the pharmacologically active nucleoside analog of GS – 461203 triphosphate. Daclatasvir 60 mg metabolism based on CYP3A substrate with initial CYP isoform.
The average total recovery dose of 400 mg Sofosbuvir was> 92% and included removal of 80%, 14% and 2, 5% in urine, feces, exhaled air. After a single dose Daclatasvir 60 mg radioactivity recovered to 88% via the faeces and 6, 6% through urine
Half the life of Sofosbuvir 400 mg and GS-331007 was 0, 4 and 27 hours, and Daclatasvir 60 mg had a half-life of 12 to 15 hours